ArriVent BioPharma, Inc. Common Stock (AVBP) - Net Assets
Based on the latest financial reports, ArriVent BioPharma, Inc. Common Stock (AVBP) has net assets worth $323.98 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($349.30 Million) and total liabilities ($25.32 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how tangible is ArriVent BioPharma, Inc. Common Stock's equity to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $323.98 Million |
| % of Total Assets | 92.75% |
| Annual Growth Rate | 65.23% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 132.35 |
ArriVent BioPharma, Inc. Common Stock - Net Assets Trend (2021–2025)
This chart illustrates how ArriVent BioPharma, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. See ArriVent BioPharma, Inc. Common Stock (AVBP) defensive interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for ArriVent BioPharma, Inc. Common Stock (2021–2025)
The table below shows the annual net assets of ArriVent BioPharma, Inc. Common Stock from 2021 to 2025. For live valuation and market cap data, see AVBP market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | $307.22 Million | +19.24% |
| 2024-09-30 | $257.65 Million | +70.30% |
| 2023-09-30 | $151.30 Million | -13.28% |
| 2022-09-30 | $174.46 Million | +323.24% |
| 2021-09-30 | $41.22 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to ArriVent BioPharma, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 35303500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.00K | 0.00% |
| Other Comprehensive Income | $14.00K | 0.00% |
| Other Components | $711.85 Million | 231.70% |
| Total Equity | $307.22 Million | 100.00% |
ArriVent BioPharma, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of ArriVent BioPharma, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cogeco Communications Inc
TO:CCA
|
$1.41 Billion |
|
Television Francaise 1 SA
PA:TFI
|
$1.41 Billion |
|
Shinkong Insurance Co Ltd
TW:2850
|
$1.41 Billion |
|
Max Stock Ltd
TA:MAXO
|
$1.41 Billion |
|
Ecovyst Inc
NYSE:ECVT
|
$1.41 Billion |
|
Zhejiang Sanwei Rubber Item Co
SHG:603033
|
$1.41 Billion |
|
Zhejiang Merit Interactive Network Technology Co Ltd Class A
SHE:300766
|
$1.41 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
$1.41 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ArriVent BioPharma, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 257,654,000 to 307,224,000, a change of 49,570,000 (19.2%).
- Net loss of 166,308,000 reduced equity.
- New share issuances of 202,631,000 increased equity.
- Other comprehensive income increased equity by 225,000.
- Other factors increased equity by 13,022,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-166.31 Million | -54.13% |
| Share Issuances | $202.63 Million | +65.96% |
| Other Comprehensive Income | $225.00K | +0.07% |
| Other Changes | $13.02 Million | +4.24% |
| Total Change | $- | 19.24% |
Book Value vs Market Value Analysis
This analysis compares ArriVent BioPharma, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.93x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.97x to 3.93x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-09-30 | $32.30 | $31.36 | x |
| 2022-09-30 | $5.21 | $31.36 | x |
| 2023-09-30 | $4.73 | $31.36 | x |
| 2024-09-30 | $8.19 | $31.36 | x |
| 2025-09-30 | $7.99 | $31.36 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ArriVent BioPharma, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -54.13%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.08x
- Recent ROE (-54.13%) is above the historical average (-55.51%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -125.19% | 0.00% | 0.00x | 1.04x | $-55.73 Million |
| 2022 | -21.15% | 0.00% | 0.00x | 1.05x | $-54.35 Million |
| 2023 | -45.83% | 0.00% | 0.00x | 1.08x | $-84.46 Million |
| 2024 | -31.24% | 0.00% | 0.00x | 1.07x | $-106.25 Million |
| 2025 | -54.13% | 0.00% | 0.00x | 1.08x | $-197.03 Million |
Industry Comparison
This section compares ArriVent BioPharma, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ArriVent BioPharma, Inc. Common Stock (AVBP) | $323.98 Million | -125.19% | 0.08x | $1.41 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About ArriVent BioPharma, Inc. Common Stock
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutati… Read more